表紙
市場調查報告書

新型冠狀病毒感染(COVID-19):藥物和疫苗管道及臨床試驗分析:2020年6月

Coronavirus Disease 2019 (COVID-19) - Pipeline and Clinical Trial Analysis - June 2020

出版商 GlobalData 商品編碼 951722
出版日期 內容資訊 英文 56 Pages
訂單完成後即時交付
價格
新型冠狀病毒感染(COVID-19):藥物和疫苗管道及臨床試驗分析:2020年6月 Coronavirus Disease 2019 (COVID-19) - Pipeline and Clinical Trial Analysis - June 2020
出版日期: 2020年07月30日內容資訊: 英文 56 Pages
簡介

生物製藥行業的建立是為了應對新型冠狀病毒感染性疾病(COVID-19)的挑戰,全球數百家公司參與了開發治療和預防性疫苗的競爭。儘管該行業已經通過立即開始藥物研究證明了自己的實力,但由於各個疾病領域的臨床試驗時間表的延遲以及監管機構的批准決定,它不允許總體研發進展。有負面的後果。如果將來有臨床試驗數據可用,則預計公司將領導治療藥物和預防性疫苗的研發。當前,治療領域是已經被批准用於其他疾病適應症的候選者。 IL-6抑製劑是其中一種產品,已作為免疫學適應症上市銷售,有望作為COVID-19治療劑獲得初步批准。從2020年第一季度到第二季度,臨床試驗的推遲穩步增長。在2020年下半年,將加大追趕力度,但要完全克服這一嚴重的延誤將是困難的。

此報告分析了COVID-19的治療和疫苗開發管道以及臨床試驗,並提供了有關管道和臨床試驗,協議以及社交媒體趨勢的信息。

內容

目錄

第1章執行摘要

第2章流行病學

  • 流行病學:截至2020年3月25日的快照
  • 流行病學:直到2020年3月25日的路徑
  • 三個受影響最大的國家的流行病學指標:直到2020年3月25日的中國發展軌跡
  • 三個受影響最大的國家的流行病學指標:直到2020年3月25日的意大利發展軌跡
  • 三個受影響最大的國家的流行病學指標:直到2020年3月25日的美國軌跡
  • 流行病學預測:美國

第3章管道概述

  • 治療學:按階段細分
  • 治療學:按分子類型分類
  • 治療方法:按開發人員類型分類
  • 治療:臨床階段的候選人(I-III期)
  • 治療方法:臨床前階段的候選人
  • 治療學:當前可用的數據
  • 疫苗:按階段細分
  • 疫苗:按開發人員類型分類
  • 疫苗:臨床和臨床前階段的候選藥物

第4章管道概述

  • 治療學:按階段細分
  • 治療學:按分子類型分類
  • 治療方法:按開發人員類型分類
  • 治療:臨床階段的候選人(I-III期)
  • 治療方法:臨床前階段的候選人
  • 治療學:當前可用的數據
  • 疫苗:按階段細分
  • 疫苗:按開發人員類型分類
  • 疫苗:臨床和臨床前階段的候選藥物

第5章臨床試驗

  • 臨床試驗:按階段細分
  • 治療劑和疫苗的臨床試驗
  • 臨床試驗:區域概述
  • 治療藥物的臨床試驗:主要贊助商
  • 臨床試驗:該行業的主要贊助商
  • 臨床試驗設計趨勢

第6章協議趨勢

第7章社交媒體趨勢

  • Twitter的主要貢獻者
  • #Covid19 #Coronavirus#患者#Flattenthecurve熱門□□趨勢推特

第8章主要發現

第9章附錄

  • 來源
  • 調查方法
  • 關於作者

第10章全局數據

  • 聯繫我們
目錄
Product Code: GDHCHT150

The biopharmaceutical industry has risen to meet the challenge posed by this novel virus: hundreds of companies across the globe have entered the race to develop a treatment and a preventive vaccine. While the industry has shown its mettle by immediately initiating research on agents for COVID-19, the progress of R&D in general has been adversely impacted, with delays in clinical trial timelines and regulatory decisions across disease areas.

Over the coming months, as trial data readouts become available, frontrunners will emerge in both the therapeutic and preventive categories. Currently, the therapeutics space is dominated by candidates already approved for other disease indications; one of these products, an IL-6 inhibitor already marketed for an immunology indication, is well positioned to win the first regulatory approval for COVID-19. The number of clinical trial delays has been steadily increasing throughout Q1 and into Q2 2020. As activity begins to pick up later in the year, trial sponsors might strive to make up for lost time, but the extensive delays will be difficult to overcome entirely.

Scope

  • Profiles of the most promising treatments and vaccines in the pipeline for COVID-19, including SWOT analyses, an overview of trials, and summaries of available data
  • An overview of the clinical trials landscape, including discussion of the approaches being adopted for therapeutic and vaccine development
  • Highlights in deal-making trends, particularly public-private partnerships
  • Proprietary expert insights on COVID-19 R&D obtained by GlobalData's investigative journalism team
  • Analysis of the impact of the outbreak on clinical trial timelines across disease areas and geographies
  • Assessment of regulatory delays associated with the pandemic
  • GlobalData poll results on topics covered in the report

Reasons to Buy

  • Stay abreast of COVID-19 R&D

Table of Contents

Table of Contents

1 Executive Summary

  • 1.1 Report Scope
  • 1.2 Navigate the COVID-19 Outbreak with GlobalData Pharma's COVID-19 Dashboard
  • 1.3 Monitor the COVID-19 Outbreak with GlobalData Epidemiology Indicators

2 Epidemiology

  • 2.1 Epidemiology: Snapshot as of March 25, 2020
  • 2.2 Epidemiology: Disease Trajectory as of March 25, 2020
  • 2.3 Epidemiology Indicators in the Top 3 Most-Affected Countries: Disease Trajectory in China as of March 25, 2020
  • 2.4 Epidemiology Indicators in the Top 3 Most-Affected Countries: Disease Trajectory in Italy as of March 25, 2020
  • 2.5 Epidemiology Indicators in the Top 3 Most-Affected Countries: Disease Trajectory in the US as of March 25, 2020
  • 2.6 Epidemiology Forecast: United States

3 Pipeline Overview

  • 3.1 Pipeline Therapeutics: Breakdown by Phase
  • 3.2 Pipeline Therapeutics: Breakdown by Molecule Type
  • 3.3 Pipeline Therapeutics: Breakdown by Type of Developer
  • 3.4 Pipeline Therapeutics: Clinical-Stage Candidates (Phase I - III)
  • 3.5 Pipeline Therapeutics: Preclinical-Stage Candidates
  • 3.6 Pipeline Therapeutics: Currently Available Data
  • 3.7 Pipeline Vaccines: Breakdown by Phase
  • 3.8 Pipeline Vaccines: Breakdown by Developer Type
  • 3.9 Pipeline Vaccines: Clinical and Preclinical-Stage Candidates

4 Pipeline Overview

  • 4.1 Pipeline Therapeutics: Breakdown by Phase
  • 4.2 Pipeline Therapeutics: Breakdown by Molecule Type
  • 4.3 Pipeline Therapeutics: Breakdown by Type of Developer
  • 4.4 Pipeline Therapeutics: Clinical-Stage Candidates (Phase I - III)
  • 4.5 Pipeline Therapeutics: Preclinical-Stage Candidates
  • 4.6 Pipeline Therapeutics: Currently Available Data
  • 4.7 Pipeline Vaccines: Breakdown by Phase
  • 4.8 Pipeline Vaccines: Breakdown by Developer Type
  • 4.9 Pipeline Vaccines: Clinical and Preclinical-Stage Candidates

5 Clinical Trials

  • 5.1 Clinical Trials: Breakdown by Phase
  • 5.2 Clinical Trials for Therapeutics and Vaccines
  • 5.3 Clinical Trials: Overview by Region
  • 5.4 Clinical Trials for Therapeutics: Leading Sponsors
  • 5.5 Clinical Trials: Leading Industry Sponsors
  • 5.6 Trends in Trial Design

6 Deal-making Trends

  • 6.1 Deal-making Trends

7 Social Media Trends

  • 7.1 Key Twitter Chatter
  • 7.2 Top Trending Tweets include #Covid19 #Coronavirus #Patients #Flattenthecurve

8 Key Findings

  • 8.1 Key Findings

9 Appendix

  • 9.1 Sources
  • 9.2 Methodology
  • 9.3 About the Authors

10 About GlobalData

  • 10.1 Contact Us